287 related articles for article (PubMed ID: 14593618)
1. [Gluco-incretin hormones in insulin secretion and diabetes].
Thorens B
Med Sci (Paris); 2003; 19(8-9):860-3. PubMed ID: 14593618
[TBL] [Abstract][Full Text] [Related]
2. [Gluco-incretin hormones in insulin secretion].
Thorens B
Med Sci (Paris); 2005 Dec; 21 Spec No():40-3. PubMed ID: 16598904
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide-1 and control of insulin secretion.
Thorens B
Diabete Metab; 1995 Dec; 21(5):311-8. PubMed ID: 8586147
[TBL] [Abstract][Full Text] [Related]
4. Overview of incretin hormones.
Efendic S; Portwood N
Horm Metab Res; 2004; 36(11-12):742-6. PubMed ID: 15655702
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.
Green BD; Gault VA; Flatt PR; Harriott P; Greer B; O'Harte FP
Arch Biochem Biophys; 2004 Aug; 428(2):136-43. PubMed ID: 15246869
[TBL] [Abstract][Full Text] [Related]
6. Enteroinsular signaling: perspectives on the role of the gastrointestinal hormones glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide in normal and abnormal glucose metabolism.
Vahl T; D'Alessio D
Curr Opin Clin Nutr Metab Care; 2003 Jul; 6(4):461-8. PubMed ID: 12806222
[TBL] [Abstract][Full Text] [Related]
7. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes.
Nauck MA; Baller B; Meier JJ
Diabetes; 2004 Dec; 53 Suppl 3():S190-6. PubMed ID: 15561910
[TBL] [Abstract][Full Text] [Related]
8. Is glucagon-like peptide 1 an incretin hormone?
Nauck MA
Diabetologia; 1999 Mar; 42(3):373-9. PubMed ID: 10096792
[TBL] [Abstract][Full Text] [Related]
9. Incretin hormones--an update.
Holst JJ; Orskov C
Scand J Clin Lab Invest Suppl; 2001; 234():75-85. PubMed ID: 11713984
[TBL] [Abstract][Full Text] [Related]
10. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Hansotia T; Drucker DJ
Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
[TBL] [Abstract][Full Text] [Related]
11. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
[TBL] [Abstract][Full Text] [Related]
12. Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility.
Miki T; Minami K; Shinozaki H; Matsumura K; Saraya A; Ikeda H; Yamada Y; Holst JJ; Seino S
Diabetes; 2005 Apr; 54(4):1056-63. PubMed ID: 15793244
[TBL] [Abstract][Full Text] [Related]
13. Incretins, insulin secretion and Type 2 diabetes mellitus.
Vilsbøll T; Holst JJ
Diabetologia; 2004 Mar; 47(3):357-366. PubMed ID: 14968296
[TBL] [Abstract][Full Text] [Related]
14. Insulinotropic effects of cholecystokinin, gastric inhibitory polypeptide and glucagon-like peptide-1 during perifusion of short-term cultured canine isolated islets.
van der Burg MP; Guicherit OR; Frölich M; Gooszen HG
Regul Pept; 1995 Dec; 60(1):61-7. PubMed ID: 8747785
[TBL] [Abstract][Full Text] [Related]
15. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
Creutzfeldt W
Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
[TBL] [Abstract][Full Text] [Related]
16. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
[TBL] [Abstract][Full Text] [Related]
17. Incretin hormones regulate glucose-dependent insulin secretion in RIN 1046-38 cells: mechanisms of action.
Montrose-Rafizadeh C; Egan JM; Roth J
Endocrinology; 1994 Aug; 135(2):589-94. PubMed ID: 8033807
[TBL] [Abstract][Full Text] [Related]
18. Prior in vitro exposure to GLP-1 with or without GIP can influence the subsequent beta cell responsiveness.
Delmeire D; Flamez D; Moens K; Hinke SA; Van Schravendijk C; Pipeleers D; Schuit F
Biochem Pharmacol; 2004 Jul; 68(1):33-9. PubMed ID: 15183115
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM.
Thorens B; Waeber G
Diabetes; 1993 Sep; 42(9):1219-25. PubMed ID: 8349031
[TBL] [Abstract][Full Text] [Related]
20. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]